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CBackground: The diagnostic algorithm for most cancers includes the
assessment of a tissue specimen by a surgical pathologist, but if spec-
imen provenance is uncertain, the diagnostic and therapeutic process
carries significant risk to the patient. Over the last decade, short tan-
dem repeat (STR) analysis has emerged as a DNA-based method with
clinical applicability for specimen identity testing (also known as spec-
imen provenance testing). Although the clinical utility of identity test-
ing using STR-based analysis has been demonstrated in many studies,
its economic value has not been established. Methods: We developed
a decision-analytic model of the application of STR-based provenance
testing of transrectal prostate biopsy specimens obtained as part of
routine clinical care to rule out the presence of adenocarcinoma of the
prostate, as comparedwith no STR-based testing. Using parameter val-
ues drawn from the published literature, the cost-effectiveness of STR-
based testing was quantified by calculating the incremental cost-
effectiveness ratio per quality-adjusted life-year gained. Results: In
comparison to the current standard practice of no identity testing, O
ology
al So
http://dx.doi.org/10.1016/j.jval.2012.04.011dentity testing by STR-based analysis has an incremental cost-effec-
iveness ratio of $65,570 per quality-adjusted life-year gained at a test-
ng cost of $618 per person. At a cost of $515 per person, identity testing
ould meet the conservative standard of $50,000 per quality-adjusted
ife-year. At a test cost of $290 per person, identity testingwould be cost
aving. Conclusion: Given the rapidly declining pricing of STR-based
dentity testing, it is likely that testing to confirm the identity of posi-
ive prostate biopsy samples will be a cost-effective method for pre-
enting treatment errors stemming from misidentification. Studies to
ormally establish the frequency of specimenprovenance errors in rou-
ine clinical practice would therefore seem justified.
eywords: incremental cost-effectiveness ratio (ICER), prostate biopsy,
hort tandem repeat analysis, specimen identity testing, quality-ad-
usted life-year (QALY).
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The diagnostic algorithm for most cancers includes the assess-
ment of a tissue specimen by a surgical pathologist. The sample is
taken from a patient with a known or suspected disease as part of
a procedure in the office or surgical suite, labeled, and transported
to the pathology lab for evaluation. The pathologist prepares the
report, which then becomes the basis for treatment decisions. Un-
derlying this series of events is the assumption that there is per-
fect continuity in the labeling and transport of the patient speci-
men that ensures that the specimen evaluated by the pathologist
corresponds to the specimen obtained from the patient. If speci-
men provenance is uncertain, the diagnostic and therapeutic pro-
cess carries significant risk to the patient [1,2].
There is an extensive literature on specimen identification er-
rors (also known as specimen provenance errors, or SPEs), which
can arise in the preanalytic (collection and processing), analytic, or
postanalytic (reporting) stages of the specimen test cycle [3–8].
Although recent reports have demonstrated that the application
of new technologies in the clinical laboratory can decrease ana-
lytic SPEs [9–11], specimen mix-ups (which are a major class of
* Address correspondence to: John D. Pfeifer, Department of Path
South Euclid Avenue, Campus Box 8118, St. Louis, MO 63110.
E-mail: pfeifer@path.wustl.edu.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.identification errors) remain a significant high-risk concern in all
surgical pathology laboratories [12,13]. Despite more than a cen-
tury of process improvement and technical innovation, the poten-
tial for specimenmix-ups, cross-contamination, floaters, or carry-
over artifacts has not been eliminated completely [3,5,14–16].
Over the last decade, short tandem repeat (STR) analysis has
emerged as a DNA-based method with clinical applicability for
specimen identity testing (also known as specimen provenance
testing). The panel of STRs (also known asmicrosatellites) utilized
in the testing is based on the Combined DNA Index System loci
originally selected by the Federal Bureau of Investigation of the
United States [17]. The Combined DNA Index System loci feature
extreme polyallelism and widespread distribution of the different
alleles across different population groups, characteristics that
provide STR-based testing with a very high power of discrimina-
tion for assigning specimen provenance in clinical settings. The
clinical utility of STR-based testing using the Combined DNA In-
dex System loci is enhanced by the ease of testing (commercial
kits for analysis are available), the availability of technical re-
sources to support test interpretation, and an extensive literature
that has demonstrated clinical utility for the resolution of a wide
variety of specimen labeling and identification issues [14,16,18].
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demonstrated in many studies, its economic value has not been
established. Nearly 40% of men with an abnormal digital rectal
exam result or an elevated prostate-specific antigen who undergo
transrectal prostate biopsies to rule out adenocarcinoma have a
positive biopsy result [19]. Given this high percentage of men with
latent disease, the occurrence of a specimen switch could fre-
quently result in a correct, albeit accidental, finding. Inmost cases,
however, the result of an SPE for the patientwould be unnecessary
morbidity and mortality associated with treatment, including the
potential for incontinence or impotence. Avoiding this iatrogenic
harm is the benefit of STR-based analysis, but a rigorous economic
evaluation to determinewhether the benefit outweighs the cost of
this test has not been performed.
We conducted an economic evaluation of the application of
STR-based provenance testing, versus no testing, of transrectal
prostate biopsy specimens obtained as part of routine clinical care
to rule out the presence of adenocarcinoma of the prostate. The
parameter values in our model were drawn from the published
literature, and we conducted extensive sensitivity analyses to
identify those factors most associated with the cost-effectiveness
of STR-based provenance testing.
Methods
We constructed a decision analytic model to compare the cost-
effectiveness of identity testing to prevent SPEs for prostate cancer
biopsies positive for cancer, versus the current practice of no iden-
tity testing. Parameters in this model included estimates of the
SPE rate in surgical pathology, the percentage ofmenbiopsiedwho
are diagnosed with prostate cancer, the usage of prostate cancer
treatments by age, and the prevalence of side effects from treat-
ment. We also included estimates for the quality-of-life effects of
different combinations of side effects from treatment. Estimates
Posi
No Identy Test 
Not Correct Correct
Cancer No Cancer 
Unnecessary Treatment 
   -Radical Prostatectomy 
   -EBRT 
   -Brachytherapy 
   -PADT 
   -Watchful Waing 
Complicaons No Complic
Dead 
Fig. 1 – Markov model to evaluate the potential adverse outc
therapy; PADT, primary androgen disruption therapy.for costs of DNA testing, prostate cancer treatment, and treatmentof side effects were applied to the model on the basis of expert
opinion and Medicare allowable. Uncertainty in the model stem-
ming fromvariability in the values of the parameterswas tested by
using one-way and two-way sensitivity analyses. Analysis was
conducted from a payer perspective, while assuming that quality-
adjusted life-year (QALY) has meaning to a third-party payer.
Costs were estimated by using the Medicare allowable.
Modeling the costs and effectiveness of identity testing for
prostate cancer biopsies
In Figure 1 we provide an illustration of the Markovmodel to eval-
uate the potential adverse outcomes of cancer treatment. The
treatment for prostate cancer differs by age, and so themodel was
stratified by age, with individuals aging throughout the modeling
process (and mortality risk adjusted accordingly). Individuals
whose specimen is correctly labeled face the same risk and benefit
in both arms of our model; therefore, their outcomes do not affect
the incremental result andarenot illustratedhere. Similarly, individ-
ualswithamislabeled specimenwhohaveprostate cancer in spite of
the mislabeled sample (i.e., a surreptitious “true positive”) also face
the same risk and benefit in both arms of themodel; therefore, their
outcomes are not illustrated and were not modeled.
We assume that genetic testing is 100% accurate; therefore, no
one in the “Identity Test” branch faces iatrogenic harm due to
misdiagnosis; however, these patients do face the cost of a second
biopsy to correct the initial erroneous diagnosis. We make the
assumption that this second biopsy is 100% accuratewith no iden-
tification error. In the “No Test” arm, misclassified patients un-
dergo treatment for their incorrectly diagnosed cancer, facing the
potential for adverse outcomes of treatment.
AMarkovmodel was constructed to estimate the cost and ben-
efit of long-term outcomes of treatment. The Markov model is a
mathematical method of representing an iterative process, in this
context, the medical/surgical process faced by a patient following
psy
Identy Test 
No Match Match 
Re-Biopsy Cancer No Cancer
Dead
s of cancer treatment. EBRT, electron beam radiationve Bio
aons
omea positive finding by the biopsy. The Markov process consists of a
862 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 6 0 – 8 6 7Table 1 – Parameters for economic model.
Variable name Default definition Sensitivity analysis low Sensitivity analysis high
Age distribution of prostate cancer patients (%) [23]
50 y 44.1 0.0 0.0
50–64 y 38.4 0.0 0.0
65–75 y 14.8 0.0 0.0
75 y 2.7 0.0 0.0
Treatment distribution by age (%) [23]
Brachytherapy
50 y 4.8 0.0 0.0
50–64 y 10.3 0.0 0.0
65–75 y 18.3 0.0 0.0
75 y 14.6 0.0 0.0
EBRT
50 y 1.9 0.0 0.0
50–64 y 5.7 0.0 0.0
65–75 y 17.1 0.0 0.0
75 y 19.9 0.0 0.0
PADT
50 y 3.5 0.0 3.5
50–64 y 5.7 0.0 5.7
65–75 y 15.7 0.0 15.7
75 y 43.2 0.0 43.2
Radical prostatectomy
50 y 88.5 0.0 0.0
50–64 y 75.7 0.0 0.0
65–75 y 41.0 0.0 0.0
75 y 2.7 0.0 0.0
WW/AS
50 y 1.3 0.0 0.0
50–64 y 2.6 0.0 0.0
65–75 y 7.9 0.0 0.0
75 y 19.6 0.0 0.0
Rate of specimen provenance complications (SPCs) (%) [13] 1.0 0 1
Rates of treatment complications (%)
Major complications from radical prostatectomy [24] 4.8 0 10
Minor complications from radical prostatectomy [24] 9.5 0 20
Surgical death following radical prostatectomy [25] 0.48 0.18 0.59
Acute side effects (%) [21,24]
Brachytherapy
Bowel complications 2.0 0.0 10.0
ED 15.0 0.0 60.0
Urinary incontinence 29.0 0.0 61.0
EBRT
Bowel complications 18.0 0.0 50.0
ED 29.0 0.0 85.0
Urinary incontinence 30.0 0.0 73.0
Radical prostatectomy
ED 77.0 0.0 90.0
Urinary incontinence 47.0 0.0 74.0
Long-term side effects (%) [21,24]
Brachytherapy
Bowel complications 2.5 0.0 10.0
ED 8.4 0.0 60.0
Urinary incontinence 6.9 0.0 61.0
EBRT
Bowel complications 4.1 0.0 50.0
ED 8.4 0.0 85.0
Urinary incontinence 5.7 0.0 73.0
Primary androgen deprivation therapy
ED [26] 69.0 0.0 100.0
Radical prostatectomy
ED 30.7 0.0 90.0
Urinary incontinence 8.6 0.0 74.0(continued on next page)
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863V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 6 0 – 8 6 7series of cycles (in this context, the cycle is equal to 1 year) during
which the patient faces consequences associated with the treat-
ment of their disease, including the risk of adverse outcomes and
additional costs [20]. In modeling side effects, we assumed that it
is possible for side effects to either develop or resolve during the
current or subsequent Markov cycle [21]. Therefore, for the first two
cycles (years), apatient couldmovebetween treatmentoptions.After
this period, the patient remains in the final treatment state for the
rest of his life and thus experiences the consequence of only that
treatment for his remaining lifetime [22].
Data and assumptions
Table 1, we present the values for the model parameters used in
themodel along with the ranges examined in sensitivity analyses,
and the data source; most were taken from the 2009 report by the
Institute for Clinical and Economic Review titled “Management
options for low-risk prostate cancer: a report on comparative ef-
fectiveness and value” [24]. From this report, estimates of the
hort- and long-term side effects, the probabilities of complica-
ions following surgery, the costs of primary treatments, and the
osts of treating side effects were determined.
The treatment decision following a diagnosis of prostate can-
er is typically based on the presumed risk of progression and age
f the patient [26]. As our relevant subgroup lacked a malignancy
o progress,we assumed that treatment decisionswould largely be
ased on the patient’s age. The treatment decision by age was
rawn from Cooperberg et al. [23].
It is important to emphasize that we did not include in the base
ase any medical-legal costs based on the error of diagnosing and
reating prostate cancer when, in fact, there was no cancer. We
id, however, experiment with including legal costs in the model;
Table 1 (continued)
Variable name Defaul
Utilities [27]
Bowel, urinary, and ED
Bowel complications
Bowel and urinary incontinence
Erectile dysfunction
ED and bowel
ED and urinary incontinence
Urinary incontinence
PADT treatment
WW/AS (20% chance)
Costs of treatment ($) [24]
Brachytherapy 10
EBRT 21
Yearly PADT 8
Radical prostatectomy 10
WW/AS 1
Prostate biopsy
STR DNA test [28]
Yearly posttreatment follow-up
Costs of side effects ($) [24]
Bowel complications 1
Erectile dysfunction
Urinary incontinence
Major complications from radical prostatectomy 17
Minor complications from radical prostatectomy 7
Discount rate (%) [29]
Probability positive biopsy (%) [30]
ED, erectile dysfunction; EBRT, electron beam radiation therapy; P
WW/AS, watchful waiting with active surveillance.he assumptions used in the experiment are that only individualsundergoing prostatectomywill sue and that any individual filing a
lawsuit will win. In 2006, Sobel et al. [31] estimated that the aver-
age award in cases involving urology was $452,855, with a median
of $185,000. We updated this average award by using data from
Perrotti et al. [32] who estimated that the average indemnity pay-
ment increased 191% between 1985 and 2004, an average of about
3.2% per year, and that the average indemnity payment increased
about 24% between 2000 and 2003 for an average of about 7.2% per
year. Thus, to test the inclusion of legal costs in the model, the
average and median award were used to construct a lognormal
distribution, and the output of that lognormal distribution was
updated by 4 years by using either a 3% inflation factor or a 7%
inflation factor. The results from the model indicate that when
using the 3% inflation factor, the cost of the no-test armwill equal
the cost of the STR test arm if between 20% and 21% of the patients
sue and that with the 7% inflation factor, the costs will be equal if
18% to 19% of the individuals file suit. This experiment indicates
that legal costs would have a significant effect on the model if
more concrete data could be obtained.
Estimating the utility of health states
To determine the effects of a treatment with an individual’s
health, a quantitative measure of quality of life must be used. In
this study, we measured quality of life in terms of “utility.” Utility
is a preference-basedmeasure that quantifies an individual’s per-
ception of the importance of functional limitation. The scale used
to measure utility ranges from 0.0 to 1.0, with zero representing a
health state comparable to death and 1.0 representing perfect
health [33]. The utilities for each health state are then used to
calculate the QALYs expected by living in that health state.
Utilities were used for three single health states and those
nition Sensitivity analysis low Sensitivity analysis high
45 0 1
71 0 1
7 0 1
89 0 1
57 0 1
79 0 1
83 0 1
83 0 1
84 0 1
5,241 20,964
10,843 43,372
4,139 16,554
5,398 21,592
513 2,050
321 1,284
50 400
256 1,022
744 2,976
253 1,012
475 1,900
8,963 35,852
3,760 15,042
0 0.0 7.0
0 26.0 41.0
primary androgen disruption therapy; STR, short tandem repeat;t defi
0.
0.
0.
0.
0.
0.
0.
0.
0.
,482
,686
,277
,796
,025
642
618
511
,488
506
950
,926
,521
3.
32.
ADT,complications resulting from active treatment, “erectile dysfunc-
864 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 6 0 – 8 6 7tion,” “urinary incontinence,” and “bowel complications,” along
with all possible combinations of these health states. Utilities
measuring the quality of life during primary androgen deprivation
therapy and watchful waiting with active surveillance were also
used in the construction of the model. All values for utility were
taken from Stewart et al. [27]. Stewart et al. obtained standard
gamble utilities for 19 health states from 162 subjects recruited as
volunteers from the San Diego, CA, area, 52% of whom had been
diagnosedwith prostate cancer. Short-termdisutility of treatment
resulting from the invasiveness of surgery and radiation therapies
was not included because the magnitude of these effects is un-
known and omitting these effects provided a conservative esti-
mate of the cost-effectiveness of identity testing.
Estimating the incremental cost-effectiveness
The incremental cost-effectiveness of one treatment compared
with another is determined by dividing the incremental cost of a
treatment by the incremental effectiveness (in the context of this
study, effectiveness is estimated by QALYs). This is known as the
incremental cost-effectiveness ratio (ICER) [34]. A treatment is
considered cost-effective if the value that society places on aQALY
is greater than the cost required to acquire the QALY via the pro-
posed treatment. This value is based on society’s “willingness to
pay” (WTP), or the value that society places on a QALY. In this
study, we used a WTP of $100,000 per QALY, regarded by many
economists as the upper bound of WTP, as well as a conservative
estimate of $50,000, as the thresholds for cost-effectiveness in
sensitivity analyses [35].
The influence of model assumptions on the ICER was tested by
using one- and two-way sensitivity analyses. The overall model
stability was evaluated with probabilistic sensitivity analysis pre-
sented as a net benefits acceptability curve [36]. This was devel-
oped from the results of a second-order Monte Carlo simulation in
which themodel resampled 10,000 times to evaluate the influence
of parameter uncertainty on the cost-effectiveness decision. As
the costs and effects of treatment occur over a patient’s remaining
lifetime, future costs and benefits were discounted at a 3% rate
[37]. The study time horizon was the patient’s lifetime, and we
took the payer perspective. All decision modeling and sensitivity
analyseswere performed by using TreeAge Pro 2009 (TreeAge Soft-
ware, Inc., Williamsport, MA).
Results
The results of our analysis are shown in Table 2. The strategies of
“no identity test” and “identity test” are ranked in order of ex-
pected lifetime cost of identity testing and treatment related to
misdiagnosis per person in the second column. The third column
represents the incremental total lifetime cost of each strategy in
comparison with the previous strategy. The fourth column is the
effectiveness of each strategy measured in QALYs gained over the
patient’s remaining lifetime. The fifth column represents the ex-
pected incremental lifetime benefit of each strategy in the number
of QALYs gained per person versus the other strategy. In this case,
Table 2 – ICER of identity testing.
Strategy Cost ($) Incremental cost ($)
No identity testing 224
Testing 624 401
ICER, incremental cost-effectiveness ratio; SPE, specimen provenanc
* Calculated assuming an STR-based DNA testing cost of $618 and an
ICER of changes in the cost of testing and SPE rate.because “identity testing” prevents unnecessary treatment, thereis a gain in QALYs lived by a simulated population. The sixth col-
umn represents the incremental cost-effectiveness of each strat-
egy. This represents the cost at which one QALY can be “pur-
chased” over those created from the previous strategy.
In comparison to the current practice of “no identity testing,”
“identity testing” has an ICER of $65,570 compared with the base-
case scenario. Assuming a cost-effectiveness threshold between
$50,000 and $100,000, “identity testing” would likely be considered
a cost-effectivemethod for preventing treatment errors stemming
from the misidentification of prostate cancer biopsies [35].
Sensitivity analysis
In one-way sensitivity analysis we found that the cost-effective-
ness decision is sensitive to the rate of SPE in prostate cancer
biopsies and the cost of the test. No other parameters with clini-
cally relevant changes in assumed value resulted in a change of
treatment decision, given a decision threshold between $50,000
and $100,000 per QALY gained.
We further evaluated the confidence that a decision-maker
might have in the cost-effectiveness decision using two-way sen-
sitivity analysis. We specifically examined the cost of DNA testing
(per person) and the SPE rate. The results are shown in Figure 2.
This figure illustrates the combination of the cost of the DNA test
and the SPE error rate for which testing would be cost-effective at
a WTP of $50,000 and $100,000. In our illustration, points to the
southeast of the WTP lines would represent combinations of ac-
curacy and cost of DNA testing thatwouldmeet these standards of
cost-effectiveness. In our base case, we used $618 per person for
the cost of DNA testing and an SPE of 1.0% (this point is illustrated
at the intersection of the vertical and horizontal lines of our
graph). At a WTP of $100,000, identity testing would be consid-
ered to be cost-effective; however, at the more conservative
standard of $50,000 per QALY typically used in other industri-
alized nations, identity testing would not be considered to be
cost-effective. Figure 2 illustrates that if we assume the “true”
SPE is 1.0 (represented by the blue vertical line), the cost of
identify testing would need to drop below $515 per person to
meet this standard of cost-effectiveness. Alternatively, if we
assume that $618 per person represents the minimum that can
be allowed for this test, the true SPE would have to be 1.15% to
meet this standard of cost-effectiveness.
In Figure 3 we present the net benefit cost-acceptability curve
for this evaluation. The price per test in this simulation is not
varied, and therefore is fixed at $618 per person. At this price of
testing, we see that theWTPmust be more than $80,000 per QALY
for there to be at least an 80% certainty that testing would be the
most cost-effective option.
Discussion
In this economic evaluationof the cost-utility of STR-based testing to
confirmthe identity of positiveprostatebiopsy samples,we foundan
ICER of $65,570 per QALY gained. This would appear to bewithin the
range normally accepted by health authorities in the United States
ffectiveness Incremental effectiveness ICER
1.07
1.08 0.006 $65,570*
r; STR, short tandem repeat.
ate of 1% as in Table 1. See Figure 2 for analysis of the impact on theE
e erro
SPE rbut is above that normally accepted by payers in Europe or Canada
865V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 6 0 – 8 6 7[33–38]. To provide additional context to this estimate, consider that
the ICER formammography inwomenyounger than50years ismore
than $200,000 per QALY gained, the ICER of using drug-eluting stents
versus bare metal stents to avoid a major cardiac event is €18,311
($25,536) [39], and the use of fluorodeoxyglucose (18F)-PET for the
diagnosis of lung cancer ranges from $16,000 to more than $200,000
per QALY depending on the pretest characteristics of the subject
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866 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 6 0 – 8 6 7quencywithwhich the errors occur. SPEs that occur at the preana-
lytic stage are especially troublesome for pathologists because
they may occur in the clinic or the operating room and are thus
completely outside the control of the pathology laboratory [6–
8,11–13]. Specimen identification issues associated with deficien-
cies in specimen labeling, mismatches between the patient name
on the container and the requisition slip, accessioning errors, and
so on occur in about 6% of the accessioned cases on the basis of the
College of American Pathologists Q-Probes study [13]. Specimen
identification issues due to a presumably extraneous tissue con-
taminant in a surgical or cytology specimen occur in about 0.6% of
the slides evaluated prospectively and 2.9% of the slides evaluated
retrospectively with the specific intent to identify contaminants
[15]; of note, about 30% of the contaminants encountered prospec-
tively are abnormal or neoplastic, and about 10% present some
degree of diagnostic uncertainty.
A limitation, however, of all published studies addressing SPEs
is that none were designed to detect occult specimen identity er-
rors although such occult errors are nonetheless known to exist as
documented by many studies [14,18,16,28,41]. The demonstrated
tility of STR-based testing to detect SPEs in the absence of any
irect indication that a specimen switch may have occurred
16,18,41] highlights the clinical utility of the approach to detect
pecimen switches that cannot be captured by current laboratory
rotocols prospectively. While the magnitude of occult specimen
witches is currently unknown, in Figure 2 we show that STR-
based testing meets a cost-effectiveness standard of $100,000 per
QALY at a wide range of combinations of clinically relevant test
costs and misclassification rates. Nonetheless, it might be of in-
terest to testmakers that our analyses found that at a cost of less
than $515 per person, STR-based identity testing would be consid-
ered to be cost-effective in non-US jurisdictions and at a cost of
less than $290 per person, STR testing would be cost saving. Sim-
ilarly, given that the true SPE rate among patients with a positive
biopsy finding is unknown, it is important to note that at an SPE
rate of 1.15%, identity testing wouldmeet the European and Cana-
dian standards of cost-effectiveness.
It is important to emphasize that standard clinical laboratory
practice incorporates over 100 years of process improvements and
technical procedures designed to eliminate specimen switches
and that recent improvements including differential specimen
inking, use of bar coding, and even implementation of radiofre-
quency identification tags have all been shown to reduce the fre-
quency of detected laboratory SPEs [9–11]. By definition, however,
real-time laboratory processes cannot detect specimen identifica-
tion errors that occur prior to the assignment of the identifier or
that occur in the clinic or the operating room before the specimen
is received by the pathology laboratory. Because the specimen
identification errors in these categories are outside the control of
the pathology laboratory, they cannot be addressed by pathology
lab–based quality assurance procedures [3–8]. The power of STR-
based specimen identification testing is that the approach makes
it possible to address SPEs along the entire test cycle, regardless of
whether the error is preanalytic (and outside the control of the
pathology laboratory), analytic, or postanalytic. As such, STR-
based specimen provenance testing is best viewed as an indepen-
dent patient safety process. This process is initiated by the clinical
physician in support of national patient safety goals and require-
ments [1,2] because the testing is capable of addressing patient
safety issues that extend from the clinic, the treatment room, or
the operating room; through transport to the pathology labora-
tory; through specimen processing and analysis; and finally
through test reporting steps. In this regard, it is noteworthy that
insurance providers, includingMedicare, pay for second (and even
third) opinions of the diagnostic interpretation of patient speci-
mens given the well-established occurrence of analytic and post-analytic errors that impact patient safety and clinical outcome
[4,42,43].
Conclusion
Our results demonstrate that STR-based testing is likely to produce a
net benefit for society by reducing iatrogenic harm for patients. As a
consequence, health policymakers should consider providing cover-
age for testing in patients undergoing prostate biopsy. While our
findings are robust, demonstration that this result is real and not an
artifact of our modeling process requires measurement of the fre-
quency of occult SPEs in routine clinical practice.
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